The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Abattis Bioceuticals signed a letter of intent with dicentra for a suite of services to support Abattis’s current and future regulatory and compliance needs.
Abattis Bioceuticals (CSE:ATT; OTC:ATTBF) signed a letter of intent with dicentra for a suite of services to support Abattis’s current and future regulatory and compliance needs.
As quoted in the press release:
Pursuant to the LOI, Abattis and dicentra have agreed to negotiate in good faith the terms of a definitive agreement respecting the Partnership, which agreement will include representations, warranties and covenants typical for an arrangement of similar nature to the Partnership and will supersede the LOI.
With more than 1,000 clients served internationally, over 15,000 projects successfully completed and offices in Canada and the United States, dicentra is a leading consulting firm with 16 years of experience providing regulatory and compliance services.
“Bringing dicentra’s experience and expertise to Abattis will help us to secure world-class regulatory and compliance services for Abattis and our clients and partners”, stated Rob Abenante, President and CEO of Abattis.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.